Immunic, Inc.
IMUX
$0.84
$0.078.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.38M | 18.15M | 18.01M | 18.09M | 17.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.27M | 101.00M | 98.05M | 95.80M | 93.65M |
| Operating Income | -105.27M | -101.00M | -98.05M | -95.80M | -93.65M |
| Income Before Tax | -101.84M | -96.40M | -100.51M | -96.90M | -95.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.84 | -96.40 | -100.51 | -96.90 | -95.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.84M | -96.40M | -100.51M | -96.90M | -95.31M |
| EBIT | -105.27M | -101.00M | -98.05M | -95.80M | -93.65M |
| EBITDA | -105.10M | -100.85M | -97.92M | -95.68M | -93.53M |
| EPS Basic | -0.94 | -0.95 | -1.01 | -1.24 | -1.51 |
| Normalized Basic EPS | -0.58 | -0.59 | -0.60 | -0.74 | -0.91 |
| EPS Diluted | -0.94 | -0.95 | -1.01 | -1.24 | -1.51 |
| Normalized Diluted EPS | -0.58 | -0.59 | -0.60 | -0.74 | -0.91 |
| Average Basic Shares Outstanding | 435.50M | 404.59M | 400.55M | 344.44M | 287.75M |
| Average Diluted Shares Outstanding | 435.50M | 404.59M | 400.55M | 344.44M | 287.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |